Related Experiment Video
Updated: Jun 4, 2026
Assay Development for High Content Quantification of Sod1 Mutant Protein Aggregate Formation in Living Cells
Published on: October 4, 2017
Chemical library screening identifies a small molecule that downregulates SOD1 transcription for drugs to treat
Gaku Murakami1, Haruhisa Inoue, Kayoko Tsukita
1Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Abstract:
Familial amyotrophic lateral sclerosis (fALS) accounts for 10% of ALS cases, and about 25% of fALS cases are due to mutations in superoxide dismutase 1 (SOD1). Mutant SOD1-mediated ALS is caused by a gain of toxic function of the mutant protein, and the SOD1 level in nonneuronal neighbors, including astrocytes, determines the progression of ALS (non-cell-autonomous toxicity). Therefore, the authors hypothesized that small molecules that reduce SOD1 protein levels in astrocytes might slow the progression of mutant SOD1-mediated ALS. They developed and optimized a cell-based, high-throughput assay to identify low molecular weight compounds that decrease SOD1 expression transcriptionally in human astrocyte-derived cells. Screening of a chemical library of 9600 compounds with the assay identified two hit compounds that selectively and partially downregulate SOD1 expression in a dose-dependent manner, without any detectable cellular toxicity. Western blot analysis showed that one hit compound significantly decreased the level of endogenous SOD1 protein in H4 cells, with no reduction in expression of β-actin. The assay developed here provides a powerful strategy for discovering novel lead molecules for treating familial SOD1-mediated ALS.
Insights
Researchers identified compounds that reduce superoxide dismutase 1 (SOD1) levels in astrocytes, potentially slowing the progression of familial amyotrophic lateral sclerosis (fALS). This discovery offers a new strategy for treating SOD1-mutant ALS.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Familial amyotrophic lateral sclerosis (fALS) constitutes 10% of ALS cases, with mutations in superoxide dismutase 1 (SOD1) accounting for 25% of fALS.
- Mutant SOD1 causes ALS through a toxic gain-of-function mechanism, where SOD1 levels in astrocytes contribute to non-cell-autonomous toxicity and disease progression.
Purpose of the Study:
- To develop and optimize a cell-based, high-throughput screening assay to identify small molecules that transcriptionally reduce SOD1 expression in astrocytes.
- To discover novel therapeutic compounds that lower SOD1 protein levels in astrocytes, potentially slowing the progression of mutant SOD1-mediated ALS.
Main Methods:
- A high-throughput screening assay was developed using human astrocyte-derived cells to identify compounds that decrease SOD1 expression.
- A chemical library of 9600 compounds was screened using the developed assay.
- Hit compounds were validated using Western blot analysis to confirm SOD1 protein level reduction and assess cellular toxicity.
Main Results:
- Screening identified two hit compounds that selectively and partially downregulate SOD1 expression in a dose-dependent manner.
- Neither hit compound exhibited detectable cellular toxicity.
- Western blot analysis confirmed that one compound significantly decreased endogenous SOD1 protein levels in H4 cells without affecting beta-actin expression.
Conclusions:
- The developed high-throughput assay is a powerful strategy for discovering lead molecules for treating familial SOD1-mediated ALS.
- The identified compounds represent promising candidates for further development as therapeutics for SOD1-ALS.
- Targeting SOD1 levels in astrocytes offers a viable therapeutic approach for non-cell-autonomous ALS progression.
